GDS Announces Partnership on Renewable Energy Initiatives
SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS), a […]
FuelCell Energy Reports Results for the Third Quarter of Fiscal 2020
Third Quarter Fiscal 2020 Highlights(All comparisons year-over-year unless otherwise noted)Revenues of $18.7 million compared to $22.7 millionOperating expenses decreased 16% […]
Check Point Software Technologies Named a Leader in the IDC MarketScape Report for Mobile Threat Management
SAN CARLOS, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of […]
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
– ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment […]
Huazhu Group Limited Launches Hong Kong Initial Public Offering
SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) — Huazhu Group Limited (Nasdaq: HTHT), a leading and fast-growing multi-brand hotel group […]
PDC Energy Launches $150 Million Tack-on Senior Notes Offering
DENVER, Sept. 10, 2020 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced that, subject to […]
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies […]
Salarius Pharmaceuticals to Present at Upcoming Investor Conferences
HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by […]
Edison Nation Launches Direct to Consumer PPE Initiative; Amazon Update
Bethlehem, P.A., Sept. 10, 2020 (GLOBE NEWSWIRE) — Edison Nation, Inc. (NASDAQ:EDNT), a multifaceted ecosystem that fosters innovation and drives […]
TSX News -
Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population
Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021Clinical study to include HIV cohortMONTREAL, […]
